Categories: News

Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity

HYDERABAD, India, August 1, 2025 /PRNewswire/ — Zenara Pharma Private Limited (“Zenara”), a Biophore company, today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sertraline Hydrochloride Capsules, 150 mg and 200 mg. This approval marks the first FDA-approved generic equivalent of the reference listed drug marketed by Almatica Pharma, LLC.

- Advertisement -

The product has also been granted Competitive Generic Therapy (CGT) designation by the FDA. As the first approved applicant under this pathway, Zenara’s ANDA has secured 180 days of marketing exclusivity in the U.S., which commenced with the product’s launch1.

- Advertisement -

Sertraline Hydrochloride Capsules are classified as selective serotonin reuptake inhibitors (SSRIs) and are indicated for the treatment of Major Depressive Disorder (MDD) in adults and Obsessive-Compulsive Disorder (OCD) in adults and pediatric patients aged six years and older.

Commenting on the milestone, Dr. Srinivas Arutla, CEO of Zenara Pharma Pvt. Ltd., said:

- Advertisement -

“Receiving the first generic approval for Sertraline Hydrochloride Capsules highlights Zenara’s strong R&D capabilities and operational excellence. We remain committed to our mission of delivering to patients, early access to high-quality, affordable pharmaceuticals.”

- Advertisement -

According to IQVIA™ sales data for the 12-month period ending June 2025, U.S. sales of the reference product totaled approximately $35.5 million.

About Zenara: 
Zenara Pharma Private Limited – a Biophore company, is a vertically integrated pharmaceutical company, committed to delivering high-quality pharmaceuticals that are safe, effective, and affordable to patients. Zenara is an industry leader in Research and Development and Manufacturing of Affordable and Quality finished dosage pharmaceutical Products. Zenara is focused on the therapeutic areas of Neurology, Orphan Drugs, Complex Products, Women’s health, Cardiology, Imaging, and Contrast Agents among others. For more information, please visit us on the web, or connect with us on our LinkedIn page.
*All brand names and trademarks are the property of their respective owners

- Advertisement -

1 U.S. FDA, Competitive Generic Therapy Approvals

- Advertisement -

Logo- https://mma.prnewswire.com/media/2742318/Zenara_Logo.jpg

View original content:https://www.prnewswire.com/in/news-releases/zenara-pharma-receives-us-fda-approval–for-first-generic-of-sertraline-hydrochloride-capsules-with-180-day-cgt-exclusivity-302519326.html

- Advertisement -
PRNW Agency

Recent Posts

Banco Sabadell Selects DXC to Advance Financial Inclusion through AI-Powered Accessibility Testing

ASHBURN, Va., Aug. 1, 2025 /PRNewswire/ -- DXC Technology (NYSE: DXC), a leading Fortune 500…

9 minutes ago

Bybit Introduces Global Credit Incentive for TradFi Platform Adoption

DUBAI, UAE, Aug. 1, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume,…

9 minutes ago

CORRECTION Sony Joins the AR Alliance to Advance the Future of Augmented Reality Wearable Devices

The following press release corrects information previously announced by AR Alliance on July 31, 2025. PISCATAWAY, N.J.,…

3 hours ago

Constellation Software Inc. and Topicus.Com Inc. Announce Results for Topicus.com Inc. for the Second Quarter Ended June 30, 2025

August 01, 2025 17:03 ET  | Source: Topicus.com Inc. TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE)…

3 hours ago

Las Vegas News Briefs August 2025

ATTRACTIONS & ENTERTAINMENTTHE FRIENDS™ EXPERIENCE FLAGSHIP LOCATION IN LAS VEGAS NOW OPEN AT MGM GRANDThe…

3 hours ago

FORTUNE ANNOUNCED FORTUNE CHINA 500 RANKINGS, SERES HAD THE BIGGEST LEAP IN 2025 RANKINGS DRIVEN BY AITO BRAND GROWTH

SERES fastest-rising company of Fortune China 2025, outpacing peers in China's competitive NEV market. CHONGQING, China,…

6 hours ago